Blog

Pushing the Boundaries in Cell Line Development: Webinar Recap

Cell Line Development /

This past February and March, Bruker Cellular Analysis, in partnership with BioProcess International, hosted a dynamic two-part webinar series – Pushing the Boundaries in Cell Line Development – spotlighting the capabilities of the Beacon® Optofluidic platform for cell line development (CLD). Now available on demand, these sessions offer a front-row view into how cutting-edge technology […]

Pushing the Boundaries in Cell Line Development: Webinar Recap Read More »

Efficiently Generating and Selecting Broadly Neutralizing Antibodies with Mosaic Nanoparticle Immunization and Multiplexed Screening

Antibody Discovery /

Therapeutic monoclonal antibodies (mAbs) have become less effective against SARS-CoV-2 infections as new variants arise due to point mutations in the spike protein that reduce antibody binding. To induce production of broadly neutralizing antibodies that target a conserved receptor-binding domain (RBD) region, protecting against multiple SARS-CoV-2 variants and zoonotic sarbecoviruses, researchers at the California Institute

Efficiently Generating and Selecting Broadly Neutralizing Antibodies with Mosaic Nanoparticle Immunization and Multiplexed Screening Read More »

AI Needs More Than Sequences to Cure Cancer – It Needs Sequence Data Linked to Functional Outcomes

Cancer Immunology, Cancer Signaling, Oncology /

“If you want to advance human health and you’re not working towards AGI [Artificial General Intelligence]/ASI [Artificial Super Intelligence] right now the 2 most important things you can be building are enabling hardware and/or scientific data sets/reliable biological data that no one else can or will create. All the ‘AGI will solve cancer’ claims are

AI Needs More Than Sequences to Cure Cancer – It Needs Sequence Data Linked to Functional Outcomes Read More »

Recent Advancements in Therapeutic Antibody Discovery: Bispecific Antibodies, ADCs, Fully Human Antibodies, and Technology Driving Antibody Discovery Forward

Antibody Discovery /

Therapeutic antibodies are transforming medicine, offering precision treatments for cancer, autoimmune diseases, and infections. Recent advancements in antibody discovery and engineering have accelerated the pace of therapeutic development, focusing on approaches such as bispecific antibodies, antibody-drug conjugates (ADCs), and fully humanized antibodies. This blog dives into recent trends and how platforms like the Beacon optofluidic

Recent Advancements in Therapeutic Antibody Discovery: Bispecific Antibodies, ADCs, Fully Human Antibodies, and Technology Driving Antibody Discovery Forward Read More »

Revolutionizing Bispecific Antibody Production Using the Beacon® Platform

Cell Line Development /

Bispecific Antibodies: An Emerging Therapeutic Paradigm Bispecific antibodies (bsAbs) are rapidly gaining momentum in the pharmaceutical industry as a revolutionary class of therapeutics. While monoclonal antibodies (mAbs) have dominated the biologics landscape for decades, bsAbs offer unique therapeutic mechanisms by targeting two different antigens simultaneously. This capability enables novel treatment strategies, particularly in cancer immunotherapy,

Revolutionizing Bispecific Antibody Production Using the Beacon® Platform Read More »

Unlocking Insights in Antibody Discovery: An Integrated Approach with the Beacon® Platform and PipeBio

Antibody Discovery /

Navigating the field of antibody discovery requires a careful balance of innovative methodologies and advanced technologies. Traditional approaches often face limitations due to biases, or risk overlooking critical insights. To overcome these challenges, a recent study delved into harnessing the combined power of Bruker’s Beacon® system and PipeBio software for antigen-specific and cross-reactive antibody discovery.

Unlocking Insights in Antibody Discovery: An Integrated Approach with the Beacon® Platform and PipeBio Read More »

Application Note: Revolutionizing Adoptive Cell Therapy Development with Bruker’s Beacon® Platform

CAR T Therapy, Cell Therapy, T Cell Profiling /

Adoptive cell therapy (ACT), the autologous or allogenic transplant of immune cells, is providing new hope in the ongoing battle against cancer. However, the path to harnessing the full potential of these therapies remains challenging, from understanding the intricate dynamics of individual cells to optimizing their therapeutic efficacy. Bruker’s Beacon® Platform emerges as a transformative

Application Note: Revolutionizing Adoptive Cell Therapy Development with Bruker’s Beacon® Platform Read More »

Exploring Species Diversity in Antibody Discovery on the Beacon® Optofluidic Platform

Antibody Discovery /

In the continually advancing field of biologics, it’s essential to search for new antibodies with distinct properties. The ability to screen primary B cells across diverse animal species broadens the diversity of recovered antibody sequences and increases the odds of finding the best antibody for any application across reagents, therapeutics, and basic health research. However,

Exploring Species Diversity in Antibody Discovery on the Beacon® Optofluidic Platform Read More »